First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy
Первое исследование применения трипептидилпептидазы 1 интравитреально у человека при ретинопатии, связанной с CLN2
2023-12-04
SCID: 54.1/jk8pypcq
Discuss with AI
CLN2 Batten diseaseintravitreal rhTPP1paracentral macular volumeretinal dystrophyspectral-domain OCT
Figures from the paper
Abstract (AI)
BACKGROUND/OBJECTIVES: CLN2 Batten Disease is a fatal neurodegenerative condition of childhood associated with retinal dystrophy and blindness. Intracerebroventricular infusion of rhTPP1 greatly slows the rate of neurodegenerative decline but not retinopathy. Intravitreal rhTPP1 is known to slow retinal degeneration in a canine model of CLN2. We report a first-in-man controlled clinical trial of intravitreal rhTPP1 for CLN2 associated retinal dystrophy. SUBJECTS/METHODS: 8 children aged 5-9 with CLN2 Batten Disease were prospectively enroled. Severely affected patients were preferentially selected, provided that vision was better than no perception of light. Children underwent 8 weekly intravitreal injections of rhTPP1 (0.2 mg in 0.05 ml) into the right eye for 12-18 months. The left eye was untreated and acts as a paired control. The primary outcome was safety based on the clinical detection of complications. A secondary outcome was paracentral macular volume (PMV) measured by spectral domain OCT. Linear regression/paired t tests were used to compare rates of decline. RESULTS: (left). 3 of the youngest patients exhibited bilateral progressive retinal thinning (p < 0.05), whereas retinal volume was stable in the remaining 5 patients. In the 3 patients undergoing retinal degeneration, the rate of PMV loss was slower in the treated vs. untreated eye (p = 0.000042, p = 0.0011, p = 0.00022). CONCLUSIONS: Intravitreal rhTPP1 appears to be a safe and effective treatment for CLN2 related retinopathy however commencement of treatment early in the course of disease is more likely to be efficacious.
Key Findings
1
Among patients with retinal degeneration, paracentral macular volume loss was significantly slower in treated eyes than untreated eyes, with p-values of 0.000042, 0.0011, and 0.00022.
2
Eight weekly injections of 0.2 mg rhTPP1 into the right eye were administered over 12–18 months, with the untreated left eye serving as a paired control.
3
No specific safety complications are reported, supporting the apparent ocular safety of intravitreal rhTPP1 in this small cohort.
4
The findings suggest intravitreal rhTPP1 may slow CLN2 retinopathy, particularly when treatment begins early in disease progression.
5
This first-in-human controlled trial evaluated intravitreal recombinant human TPP1 (rhTPP1) for CLN2-associated retinal dystrophy in eight children aged 5–9 years.
6
Three youngest patients showed significant bilateral progressive retinal thinning, while retinal volume remained stable in five patients.
Research Object
CLN2-associated retinal dystrophy in children with CLN2 Batten disease
Research Subject
The safety and effect of intravitreal recombinant human tripeptidyl peptidase 1 (rhTPP1) on the rate of retinal degeneration, assessed by paracentral macular volume
Publication Details
Publication Date
2023-12-04
Journal
Publisher
ISSN
Cited by
10
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function2013
Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease2020
An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy2021